Drugs Containing Excipient (Inactive Ingredient) GLYCERYL DISTEARATE

« Back to Dashboard

Branded drugs containing GLYCERYL DISTEARATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
RedHill Biopharma Ltd	AEMCOLO	rifamycin	57841-1200	GLYCERYL DISTEARATE	2028-11-16
Aries Pharmaceuticals Inc	AEMCOLO	rifamycin	71068-001	GLYCERYL DISTEARATE	2028-11-16

Generic drugs containing GLYCERYL DISTEARATE excipient

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	estradiol	0378-8770	GLYCERYL DISTEARATE
Lannett Company Inc	bupropion hydrochloride	0527-2415	GLYCERYL DISTEARATE
Sandoz Inc	bupropion hydrochloride	0781-5528	GLYCERYL DISTEARATE
Rising Pharma Holdings Inc	esomeprazole magnesium	16571-880	GLYCERYL DISTEARATE
Macleods Pharmaceuticals Limited	esomeprazole	33342-306	GLYCERYL DISTEARATE
Quality Care Products LLC	ondansetron	35356-197	GLYCERYL DISTEARATE
Rebel Distributors Corp	ondansetron	42254-077	GLYCERYL DISTEARATE

Glyceryl Distearate Market Dynamics, Pharmaceutical Demand, and Financial Trajectory

Last updated: September 26, 2026

Glyceryl distearate is a mature, low-cost pharmaceutical excipient used mainly in oral solid dosage and lipid-based formulations. Its market is fragmented, with demand driven by tablet production, formulation optimization, and specialty-grade qualification rather than by standalone intellectual property. Public company filings generally do not report glyceryl distearate revenue separately, so financial analysis must rely on excipient portfolios, volume trends, raw-material economics, and formulation demand.

The strongest commercial characteristics are recurring demand, broad geographic sourcing, and relatively low switching costs before qualification. The main constraints are commodity price exposure, product-name ambiguity, limited differentiation, and substitution by glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, hydrogenated vegetable oils, magnesium stearate, and other lipid excipients.

What is glyceryl distearate and how is it used in pharmaceuticals?

Glyceryl distearate is a glycerol ester of stearic acid. Commercial material can contain related monoester and triester fractions, so grade specifications matter. It should not be treated as interchangeable with glyceryl monostearate, glyceryl behenate, or glyceryl palmitostearate.

Typical pharmaceutical functions include:

Function	Pharmaceutical application	Commercial value
Lubricant	Tablets and capsules	Low to moderate
Anti-adherent	Direct compression and granulation	Low to moderate
Hydrophobic matrix former	Modified-release tablets	Moderate
Lipid carrier	Poorly water-soluble active ingredients	Moderate to high
Processing aid	Powder flow and compaction	Low to moderate
Coating or dispersion component	Oral multiparticulates and lipid systems	Moderate

The economic value depends on the grade. Standard material competes mainly on price and supply reliability. High-purity, narrow-distribution, low-peroxide, and validated pharmaceutical grades command higher margins because customers must qualify them in a drug product.

The main technical variables are fatty-acid composition, monoester and diester content, iodine value, acid value, hydroxyl value, melting range, particle size, residual solvents, microbial quality, and peroxide formation. These variables affect tablet hardness, dissolution, release rate, powder flow, and stability.

How large is the pharmaceutical glyceryl distearate market?

No authoritative public source reports a standalone global revenue figure for pharmaceutical glyceryl distearate. Market reports that aggregate glyceryl esters, stearates, lipid excipients, or pharmaceutical excipients are not reliable substitutes for a product-specific market value.

The market is best understood as a subsegment of three overlapping categories:

1. Pharmaceutical excipients for oral solid dosage.
2. Lipid-based excipients for modified release and solubility enhancement.
3. Food, cosmetic, and personal-care glyceryl esters.

Pharmaceutical consumption is likely much smaller than food and cosmetics consumption. Food and personal-care applications provide manufacturing scale, while pharmaceutical sales provide higher specification requirements and better unit economics.

What drives demand for glyceryl distearate?

Demand is linked to:

• Growth in generic oral solid dosage manufacturing.
• Expansion of contract development and manufacturing organizations.
• Increased formulation work on poorly soluble APIs.
• Use of lipid matrices for extended-release products.
• Growth in emerging-market tablet production.
• Reformulation of products to improve manufacturability or dissolution.
• Qualification of excipients with stronger traceability and impurity controls.

Demand is less exposed to a single blockbuster product than an API market. A formulation can use only a small quantity of glyceryl distearate, but thousands of products may consume the material over long commercial periods.

What is the financial trajectory for glyceryl distearate?

The financial trajectory is stable to moderately positive in volume, with limited structural pricing power. Revenue growth depends more on pharmaceutical production volumes and premium-grade mix than on rapid expansion of the excipient’s unit price.

Financial driver	Direction	Effect on suppliers
Oral solid dosage volumes	Positive	Supports recurring demand
Generic drug competition	Mixed	Raises volume but compresses formulation budgets
Specialty-grade qualification	Positive	Improves margins and retention
Stearic acid and palm-oil inputs	Volatile	Compresses gross margin during cost spikes
Energy and freight costs	Volatile	Raises delivered cost
Regulatory documentation	Positive for qualified suppliers	Raises barriers to entry
Product substitution	Negative	Limits price increases
Food and cosmetic diversification	Positive	Improves plant utilization

A base-case financial outlook would include modest volume growth, flat to low-single-digit price growth for standard grades, and stronger growth for specialty pharmaceutical grades. Gross margins should be highest where suppliers offer validated particle engineering, tighter compositional control, low-peroxide specifications, regulatory support, and reliable global supply.

What limits profitability?

Glyceryl distearate has limited intrinsic pricing power because:

• The chemistry is mature.
• The raw materials are widely available.
• Multiple suppliers can produce related glyceride grades.
• Customers can often reformulate with other lubricants or lipid excipients.
• Standard grades are frequently purchased through distributors.
• The active ingredient, not the excipient, usually determines product economics.

Profitability improves when the supplier is qualified in a regulated product and changing the excipient would require comparative dissolution, stability, process validation, and regulatory documentation.

Which companies supply glyceryl distearate and related pharmaceutical grades?

The competitive landscape is fragmented. Suppliers may sell under a precise glyceryl distearate name, a broader glyceride designation, or a proprietary excipient family. Product identity must be confirmed through the current specification and certificate of analysis.

Relevant competitive groups include:

Supplier group	Competitive position
Global specialty-excipient companies	Strong regulatory support and multinational supply
Oleochemical manufacturers	Cost advantage and raw-material integration
Pharmaceutical excipient specialists	Higher documentation and formulation support
Regional producers	Lower delivered cost in local markets
Distributors and repackagers	Availability and small-batch convenience

Companies active in adjacent lipid excipient categories include Gattefossé, BASF, Croda, IOI Oleo, Peter Greven, ABITEC, DFE Pharma, and regional oleochemical producers. Their relevant products may be glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, or other glycerides rather than glyceryl distearate itself.

Product comparisons should therefore use technical specifications, not trade names alone.

What formulations are protected by glyceryl distearate patents?

Glyceryl distearate itself is unlikely to provide meaningful standalone patent exclusivity. It is an old chemical class, and broad composition claims would face substantial prior-art barriers.

Patent value is more likely to arise from:

• A specific drug formulation containing glyceryl distearate.
• A controlled-release matrix with defined dissolution performance.
• A multiparticulate or pellet system.
• A process that produces a specified particle-size distribution.
• A combination of glyceryl distearate with polymers, surfactants, or other lipids.
• A formulation that improves bioavailability or stability.
• A manufacturing process that reduces degradation or batch variability.

Such patents generally protect the drug product or manufacturing process, not the excipient as a commercial commodity.

How strong is the patent estate for glyceryl distearate?

The standalone patent estate is weak as a barrier to entry. Competitive protection depends on know-how, customer qualification, regulatory files, manufacturing consistency, and supply agreements.

Protection type	Likely strength
Broad patent on glyceryl distearate	Low
Patent on a drug formulation using it	Moderate to strong, depending on claim scope
Process patent for specialty-grade production	Moderate
Trade secret manufacturing know-how	Moderate
Customer qualification history	Moderate to strong
Regulatory documentation package	Moderate
Brand and distribution network	Moderate

What is the FDA regulatory status of glyceryl distearate?

Glyceryl distearate is used as an inactive ingredient in drug products. The FDA Inactive Ingredient Database is the principal public reference for prior use in approved drug products and routes of administration (U.S. Food and Drug Administration, n.d.-a).

The regulatory position differs from that of an active pharmaceutical ingredient:

• It does not receive an independent FDA approval as a drug.
• It is assessed as part of the finished drug product.
• Its acceptable use depends on route, dosage form, concentration, quality, and product-specific safety information.
• A supplier may need to support an applicant’s CMC, excipient qualification, impurity, and stability packages.
• Pharmaceutical-grade claims must be supported by applicable compendial or internal specifications.

FDA guidance identifies excipient composition, manufacturing controls, impurities, and supplier oversight as relevant to drug-product quality (U.S. Food and Drug Administration, 2007).

Does glyceryl distearate have Orange Book listings?

No standalone Orange Book listing should be expected for glyceryl distearate. The Orange Book lists approved drug products and certain associated patents and exclusivity information, not excipients as independent products (U.S. Food and Drug Administration, n.d.-b).

If glyceryl distearate is used in a branded drug, any listed patents generally cover the drug, formulation, method of treatment, or manufacturing process. The excipient does not independently create Orange Book exclusivity.

Do Paragraph IV challenges affect glyceryl distearate?

Paragraph IV litigation applies to ANDA applicants challenging patents listed for a reference drug. It does not apply to glyceryl distearate as an excipient commodity.

A glyceryl-dis tearate supplier can still be commercially affected by Paragraph IV activity when:

• A generic manufacturer launches a drug product using the excipient.
• A branded formulation patent claims the use of a particular lipid matrix.
• The excipient is part of a drug product subject to formulation litigation.
• A settlement delays generic entry and postpones excipient demand.

The litigation risk attaches to the finished drug and its patents, not normally to the excipient.

What patent litigation and settlement risks affect suppliers?

Direct patent litigation over glyceryl distearate is likely to be limited. The more relevant risks are contractual and regulatory:

• Failure to meet a customer’s approved specification.
• Batch-to-batch variability affecting dissolution.
• Contamination or oxidation.
• Mislabeling of glyceryl distearate versus another glyceride.
• Breach of supply or quality agreements.
• Infringement claims involving a drug formulation or manufacturing process.
• Changes in raw-material origin that trigger requalification.

Settlement agreements in pharmaceutical patent disputes can affect demand timing, but they usually remain confidential and are not reported as excipient-specific transactions.

Are there licensing deals for glyceryl distearate?

Licensing activity is more likely to involve a formulation platform, drug-delivery technology, or proprietary excipient blend than glyceryl distearate alone.

Commercial arrangements may include:

• Long-term supply agreements.
• Preferred-supplier status.
• Technology-transfer agreements.
• Contract manufacturing arrangements.
• Joint development of lipid-based formulations.
• Regional distribution rights.
• Excipient master files or regulatory-support packages.

Public filings rarely identify glyceryl distearate-specific licensing revenue. Suppliers generally monetize the product through sales, technical support, and formulation relationships rather than royalty-bearing intellectual property.

What manufacturing and supply-chain barriers affect the market?

The main manufacturing barrier is not chemical synthesis complexity. It is consistent production at pharmaceutical quality.

Important barriers include:

• Reliable stearic-acid sourcing.
• Control of fatty-acid composition.
• Consistent esterification and fractionation.
• Low peroxide and impurity levels.
• Control of polymorphism and melting behavior.
• Prevention of oxidation during storage.
• Validated cleaning and cross-contamination controls.
• Pharmaceutical-quality documentation.
• Change-control discipline.
• Global regulatory support.

Raw-material exposure is significant. Stearic acid can be derived from palm, palm-kernel, tallow, or other feedstocks. Customers may impose requirements related to sustainability, animal origin, allergen status, genetically modified materials, and supply-chain traceability.

Geographic supply is broad, but pharmaceutical buyers often maintain dual sourcing because an excipient interruption can stop finished-drug production even when the excipient represents a small share of product cost.

How does glyceryl distearate compare with competing excipients?

Excipient	Main advantage	Main disadvantage	Competitive relationship
Magnesium stearate	Low cost and established tablet lubrication	Can affect dissolution and hydrophobicity	Direct lubricant substitute
Glyceryl monostearate	Broad availability and lipid functionality	Different melting and release behavior	Partial substitute
Glyceryl behenate	Strong modified-release and lipid-matrix performance	Higher specialty cost	Higher-value substitute
Glyceryl palmitostearate	Useful for lipid matrices and release control	Grade variability	Close technical substitute
Hydrogenated vegetable oil	Processing and lubrication utility	Different release and compaction profile	Partial substitute
Stearic acid	Low cost and familiar chemistry	Less versatile in some formulations	Basic substitute
Colloidal silicon dioxide	Flow improvement	Does not replace lipid functionality	Functional complement

Glyceryl distearate is most defensible where it produces a specific dissolution, compaction, or stability profile that is difficult to replicate with a lower-cost lubricant.

What generic launch scenarios exist for glyceryl distearate?

Glyceryl distearate demand can respond to generic launches in three ways:

1. Volume expansion: a generic uses the same or similar excipient and creates incremental demand.
2. Supplier substitution: the generic sponsor selects a lower-cost supplier after development.
3. Formulation substitution: the sponsor uses a different lubricant or release-controlling lipid.

The first commercial supplier to qualify a grade may retain business during launch, but that position can weaken after multiple sources are approved. Excipient suppliers with global inventory, regulatory support, and technical troubleshooting have better retention than commodity-only suppliers.

What is the geographic outlook?

Asia-Pacific is likely to remain the largest manufacturing base for volume-sensitive pharmaceutical and oleochemical supply. India and China are important generic-drug production centers and significant excipient markets. Europe and North America carry higher documentation, quality, and sustainability requirements, which support premium-grade suppliers.

Regional economics differ:

Region	Market characteristic
North America	High regulatory expectations and strong generic demand
Europe	Strong sustainability, compendial, and supply-chain controls
India	Large generic manufacturing base and price sensitivity
China	Broad manufacturing capacity and competitive pricing
Latin America	Import dependence and distributor-led supply
Middle East and Africa	Smaller volumes with supply continuity concerns

What is the investment outlook for glyceryl distearate suppliers?

Glyceryl distearate is more attractive as part of a diversified excipient portfolio than as a standalone growth asset. Investment cases improve when a supplier has:

• Integrated oleochemical raw materials.
• A broad portfolio of lipid excipients.
• Pharmaceutical-grade manufacturing.
• Strong presence with generic manufacturers.
• Regulatory support in the United States, Europe, and Asia.
• Dual-source or multi-site production.
• Specialty grades with documented formulation performance.
• Exposure to both pharmaceutical and non-pharmaceutical customers.

The main downside risks are raw-material inflation, customer concentration, quality failures, substitution, commoditization, and limited disclosure of product-level revenue.

Key Takeaways

• Glyceryl distearate is a mature pharmaceutical excipient with recurring but price-sensitive demand.
• Public filings do not provide a dependable standalone market-size or revenue series.
• Pharmaceutical growth should be modest and linked to oral solid dosage, generic drugs, modified release, and lipid-based formulation development.
• Specialty pharmaceutical grades have better margins than commodity material.
• The standalone patent estate is weak; protection usually resides in drug formulations, processes, qualification history, and manufacturing know-how.
• Orange Book listings and Paragraph IV challenges attach to finished drug products, not glyceryl distearate itself.
• Raw-material prices, oxidation control, compositional consistency, and regulatory documentation determine supplier competitiveness.
• Glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, magnesium stearate, and hydrogenated oils are the main competitive alternatives.
• The best commercial position belongs to suppliers that combine manufacturing scale with pharmaceutical-grade documentation and formulation support.

FAQs

Is glyceryl distearate the same as glyceryl monostearate?

No. Both are glycerol esters of fatty acids, but their ester distribution, melting behavior, and formulation performance differ. They should not be substituted without formulation and regulatory evaluation.

Is glyceryl distearate suitable for modified-release tablets?

It can be used as a hydrophobic lipid matrix former, but performance depends on grade composition, concentration, particle size, API properties, and the presence of polymers or surfactants.

Does glyceryl distearate require a Drug Master File?

A Drug Master File is not automatically required for every excipient. A supplier may use a regulatory support package, certificate of suitability, customer-specific documentation, or other CMC materials depending on the jurisdiction and drug application.

Is glyceryl distearate derived from palm oil?

It may be derived from palm-based, tallow-based, or other fatty-acid feedstocks. Origin is grade- and supplier-specific and must be verified through the supplier’s documentation.

Can glyceryl distearate be replaced without a new drug application?

A substitution may require formulation studies, comparative dissolution, stability data, process assessment, and regulatory reporting. The required pathway depends on the product, jurisdiction, change magnitude, and approved quality agreement.

References

1. European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia (11th ed.). Council of Europe.

2. International Pharmaceutical Excipients Council. (2020). The IPEC-PQG good manufacturing practices guide for pharmaceutical excipients. IPEC.

3. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary, USP 47-NF 42. U.S. Pharmacopeial Convention.

4. U.S. Food and Drug Administration. (2007). Guidance for industry: Q8(R2) pharmaceutical development. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (n.d.-a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

6. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

7. U.S. Food and Drug Administration. (n.d.-c). Drug master files. https://www.fda.gov/drugs/drug-master-files-dmfs/ drug-master-files-guidance-documents-controls-and-submissions